H.C. Wainwright lowered the firm’s price target on Akero Therapeutics to $40 from $64 and keeps a Buy rating on the shares. The analyst is “disappointed” by the SYMMETRY trial result but believes the market overreacted. The firm believes yesterday’s share selloff losses sight of the perspective that the F2-F3 NASH indication has always been the main value driver for Akero shares. The main fibrotic nonalcoholic steatohepatitis opportunity alone is worth double the current share price, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AKRO:
- 89bio price target lowered to $27 from $34 at RBC Capital
- Akero Therapeutics price target lowered to $36 from $60 at Evercore ISI
- 89bio price target lowered to $29 from $49 at Evercore ISI
- Akero Therapeutics price target lowered to $41 from $62 at JPMorgan
- Akero Therapeutics removed from Analyst Focus List at JPMorgan